Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Future US Purchases Of Lilly’s Bamlanivimab Will Depend On Success Of Outpatient Infusion Process

Executive Summary

HHS reverses course on cost sharing for the antibody and says patients will not have to pay. Operation Warp Speed will watch ‘extremely carefully’ to see if the health care system is able to adapt its practices to safely administer to the drug for COVID-19, officials say at a media briefing. FDA-authorized dose of the drug is not too low, Woodcock says.

You may also be interested in...



US FDA Authorizes Lilly’s COVID-19 mAB Combo For Lower Doses Than Tested In Phase III

The doses of bamlanivimab and etesevimab authorized for use in combination are a fraction of those shown to be effective in the Phase III BLAZE-1 trial; however, Phase II data, PK/PD modeling and in vitro data suggest the lower doses will have the same clinical impact as the higher-dose regimen, the FDA said.

Lilly’s Neutralizing Antibodies Reduce Risk Of Serious COVID-19 Outcomes By 70%

The bamlanivimab/etesevimab combo, filed for US emergency authorization in November, shows ability to reduce risk of hospitalization or death in COVID-19 patients. Lilly also sees prevention role for bamlanivimab.

Monoclonal Antibodies For COVID Suffer Access Problems Due To Limited Infusion Reimbursement

Unused supply for the Lilly and Regeneron therapies has policymakers considering Medicare payment changes for providers managing outpatient infusion, but those may require legislation. National Academies of Sciences, Engineering and Medicine committee considers the ‘paradox of unused supply with a relatively scarce product’ and tries to dissect the challenges that may be contributing to the unexpected lack of take-up for the mABs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS143269

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel